The role of Preclinical and Clinical Pharmacology is to maximize the likelihood of success of an identified candidate, or to quickly remove a likely unsuccessful candidate from progressing into further testing. The primary objective of the Pharmacology Core (Core B) is to provide the investigators of the Martin Deianey Collaboratory to Eradicate HlV-1 Infection with the pharmacologic expertise to study therapeutic strategies that reduce the latent viral pool and animal model systems, and to evaluate the pharmacologic basis of viral persistence in humans. The Pharmacology Core will coordinate access to chemical libraries, assist with lead candidate production scale-up, coordinate animal toxicology studies, analyze biological matrices for drug concentrations (both antiretroviral and induction/eradication compounds), provide pharmacokinetic/ pharmacodynamic (PK/PD) modeling for optimal dose and dose frequency selection, and perform trial simulation to optimize design and sampling strategies. This Core will participate in all aspects of drug development for identifying and progressing lead induction/eradication candidates. The Core leadership team (Drs. Kashuba and Tan) has over 20 years combined experience in preclinical and clinical pharmacology, analytical chemistry, and Core management, and are well-suited to support the projects in the Collaboratory. This results in a Core which combines academic and industry resources to synergize strengths.
The majority of drugs in development will not make it to market. The role of Preclinical and Clinical Pharmacology is to maximize the likelihood that a drug will be successful, or to identify and quickly remove a drug that will likely not be successful in going to market. This Core will provide support for all aspects of animal and human pharmacologic testing for induction/eradication compounds to support the investigators in the 4 Objectives of this proposal.
|Beliakova-Bethell, Nadejda; Hezareh, Marjan; Wong, Joseph K et al. (2017) Relative efficacy of T cell stimuli as inducers of productive HIV-1 replication in latently infected CD4 lymphocytes from patients on suppressive cART. Virology 508:127-133|
|Martin, Alyssa R; Pollack, Ross A; Capoferri, Adam et al. (2017) Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity. J Clin Invest 127:651-656|
|Yek, Christina; Massanella, Marta; Peling, Tashi et al. (2017) Evaluation of the Aptima HIV-1 Quant Dx Assay for HIV-1 RNA Quantitation in Different Biological Specimen Types. J Clin Microbiol 55:2544-2553|
|Lee, Sook-Kyung; Zhou, Shuntai; Baldoni, Pedro L et al. (2017) Quantification of the Latent HIV-1 Reservoir Using Ultra Deep Sequencing and Primer ID in a Viral Outgrowth Assay. J Acquir Immune Defic Syndr 74:221-228|
|Boehm, Daniela; Ott, Melanie (2017) Flow Cytometric Analysis of HIV-1 Transcriptional Activity in Response to shRNA Knockdown in A2 and A72 J-Lat Cell Lines. Bio Protoc 7:|
|Chaillon, Antoine; Nakazawa, Masato; Wertheim, Joel O et al. (2017) No Substantial Evidence for Sexual Transmission of Minority HIV Drug Resistance Mutations in Men Who Have Sex with Men. J Virol 91:|
|Sung, Julia A; Sholtis, Katherine; Kirchherr, Jennifer et al. (2017) Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells. EBioMedicine 23:52-58|
|Akrami, Kevan; Coletta, Joelle; Mehta, Sanjay et al. (2017) Gordonia sternal wound infection treated with ceftaroline: case report and literature review. JMM Case Rep 4:e005113|
|Gianella, Sara; Taylor, Jeff; Brown, Timothy R et al. (2017) Can research at the end of life be a useful tool to advance HIV cure? AIDS 31:1-4|
|Bosque, Alberto; Nilson, Kyle A; Macedo, Amanda B et al. (2017) Benzotriazoles Reactivate Latent HIV-1 through Inactivation of STAT5 SUMOylation. Cell Rep 18:1324-1334|
Showing the most recent 10 out of 209 publications